Mankind Pharma Limited Share Price & Analysis
₹2,332Updated 5 Jun 2026, 03:30 pm IST
LTP
₹2,332
—
Open
₹2,354.2
High
₹2,371.7
Low
₹2,331
Close
₹2,353
52W High
₹2,727
52W Low
₹1,910
Volume
160K
Lot Size
225
Sector
Healthcare
Market Cap
₹95K Cr
Face Value
₹1
Large CapNIFTY 200NIFTY 500MIDCAP 100
Price Chart
Fundamentals
P/E
47.2
Sector P/E
48.9
P/B
5.9
EPS
₹43.11
ROE
13.1%
ROCE
13.5%
D/E Ratio
0.39
Div Yield
0.04%
Book Value
₹395
+
Strengths
- ✓Low debt relative to equity (D/E 0.4x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,783 | ₹4.3L Cr | 34.4 | 5.12 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹6,616 | ₹1.7L Cr | 66.1 | 10.48 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,416 | ₹1.5L Cr | 66.4 | 17.81 | 27.6 | 15.4 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,315 | ₹1.2L Cr | 59.5 | 12.62 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,402 | ₹1.1L Cr | 27.3 | 3.29 | 12.4 | 16.6 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,091 | ₹1.1L Cr | 20 | 4.05 | 21.2 | 21.2 | 0.38 |
| DRREDDY Dr. Reddy's Laboratories Limited | ₹1,283 | ₹1.1L Cr | 25.4 | 2.83 | 11.8 | 13.6 | 0.16 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
MANKIND · as of Mar 2026
Promoters72.70%
FII12.92%▼0.42
DII11.47%▲0.42
Public2.89%
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 76.50% | 74.88% | 74.87% | 74.87% | 72.71% | 72.70% |
| FII | 6.74% | 9.87% | 11.58% | 12.37% | 13.34% | 12.92% |
| DII | 9.78% | 11.14% | 9.94% | 9.91% | 11.05% | 11.47% |
| Public | 6.97% | 4.10% | 3.61% | 2.86% | 2.89% | 2.89% |
Corporate Events
To consider and approve the financial results for the period ended March 31, 2026
Results18 May 2026
Interim Dividend - Re 1 Per Share
Dividend7 Aug 2025
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3.6K Cr ▼3.5% | ₹3.7K Cr ▲3.6% | ₹3.6K Cr ▲15.9% | ₹3.1K Cr ▼3.8% | ₹3.2K Cr ▲4.5% | ₹3.1K Cr ▲6.7% | ₹2.9K Cr ▲18.4% | ₹2.4K Cr |
| Op. Profit | ₹919 Cr ▼0.2% | ₹921 Cr ▲8.7% | ₹847 Cr ▲24.0% | ₹683 Cr ▼16.3% | ₹816 Cr ▼3.7% | ₹847 Cr ▲26.0% | ₹672 Cr ▲14.7% | ₹586 Cr |
| OPM | 26.0% ▲4.0% | 25.0% ▲4.2% | 24.0% ▲9.1% | 22.0% ▼15.4% | 26.0% ▼7.1% | 28.0% ▲21.7% | 23.0% ▼4.2% | 24.0% |
| Net Profit | ₹414 Cr ▼20.4% | ₹520 Cr ▲16.9% | ₹445 Cr ▲4.7% | ₹425 Cr ▲10.4% | ₹385 Cr ▼41.6% | ₹659 Cr ▲21.4% | ₹543 Cr ▲13.8% | ₹477 Cr |
| EPS (₹) | 9.9 ▼20.1% | 12.39 ▲16.7% | 10.62 ▲4.1% | 10.2 ▲10.6% | 9.22 ▼43.5% | 16.31 ▲21.8% | 13.39 ▲13.9% | 11.76 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹14.3K Cr ▲17.0% | ₹12.2K Cr ▲19.0% | ₹10.3K Cr ▲17.3% | ₹8.7K Cr ▲12.4% | ₹7.8K Cr ▲25.2% | ₹6.2K Cr ▲6.0% | ₹5.9K Cr ▲75.9% | ₹3.3K Cr |
| Expenses | ₹10.7K Cr ▲16.1% | ₹9.2K Cr ▲18.6% | ₹7.7K Cr ▲13.1% | ₹6.8K Cr ▲18.3% | ₹5.8K Cr ▲26.9% | ₹4.6K Cr ▲3.1% | ₹4.4K Cr ▲61.1% | ₹2.7K Cr |
| Op. Profit | ₹3.6K Cr ▲19.5% | ₹3.0K Cr ▲20.2% | ₹2.5K Cr ▲32.3% | ₹1.9K Cr ▼4.5% | ₹2.0K Cr ▲20.7% | ₹1.6K Cr ▲14.7% | ₹1.4K Cr ▲145.4% | ₹586 Cr |
| OPM | 25.0% ▲0.0% | 25.0% ▲0.0% | 25.0% ▲13.6% | 22.0% ▼15.4% | 26.0% ▼3.7% | 27.0% ▲8.0% | 25.0% ▲38.9% | 18.0% |
| Other Income | ₹241 Cr ▼56.0% | ₹548 Cr ▲85.8% | ₹295 Cr ▲109.2% | ₹141 Cr ▼32.9% | ₹210 Cr ▲14.8% | ₹183 Cr ▲50.0% | ₹122 Cr ▲60.5% | ₹76 Cr |
| Interest | ₹639 Cr ▲47.9% | ₹432 Cr ▲1170.6% | ₹34 Cr ▼26.1% | ₹46 Cr ▼23.3% | ₹60 Cr ▲185.7% | ₹21 Cr ▼8.7% | ₹23 Cr ▲1050.0% | ₹2 Cr |
| Depreciation | ₹886 Cr ▲42.7% | ₹621 Cr ▲64.3% | ₹378 Cr ▲16.0% | ₹326 Cr ▲95.2% | ₹167 Cr ▲40.3% | ₹119 Cr ▲20.2% | ₹99 Cr ▲153.8% | ₹39 Cr |
| PBT | ₹2.3K Cr ▼7.5% | ₹2.5K Cr ▲5.1% | ₹2.4K Cr ▲43.6% | ₹1.7K Cr ▼15.4% | ₹2.0K Cr ▲16.7% | ₹1.7K Cr ▲17.7% | ₹1.4K Cr ▲131.6% | ₹621 Cr |
| Tax % | 17.0% ▼15.0% | 20.0% ▲5.3% | 19.0% ▼13.6% | 22.0% ▼15.4% | 26.0% ▲8.3% | 24.0% ▼11.1% | 27.0% ▼6.9% | 29.0% |
| Net Profit | ₹1.9K Cr ▼3.6% | ₹2.0K Cr ▲3.6% | ₹1.9K Cr ▲48.2% | ₹1.3K Cr ▼9.8% | ₹1.5K Cr ▲12.4% | ₹1.3K Cr ▲22.4% | ₹1.1K Cr ▲137.3% | ₹445 Cr |
| EPS (₹) | 46.34 ▼4.0% | 48.26 ▲1.1% | 47.75 ▲49.2% | 32 ▼10.6% | 35.78 ▲13.3% | 31.59 ▲22.8% | 25.72 ▼88.3% | 219.33 |
| Div Payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% ▼100.0% | 24.0% | 0.0% | 0.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||
| Equity Capital | ₹41 Cr ▲0.0% | ₹41 Cr ▲0.0% | ₹41 Cr ▲2.5% | ₹40 Cr ▲0.0% | ₹40 Cr ▲0.0% | ₹40 Cr ▲0.0% | ₹40 Cr ▲0.0% | ₹40 Cr ▲100.0% | ₹20 Cr |
| Reserves | ₹16.3K Cr ▲6.7% | ₹15.2K Cr ▲6.7% | ₹14.3K Cr ▲53.3% | ₹9.3K Cr ▲26.1% | ₹7.4K Cr ▲20.9% | ₹6.1K Cr ▲30.6% | ₹4.7K Cr ▲35.9% | ₹3.4K Cr ▲69.3% | ₹2.0K Cr |
| Borrowings | ₹6.3K Cr ▼24.6% | ₹8.4K Cr ▼1.7% | ₹8.5K Cr ▲4011.6% | ₹207 Cr ▲21.8% | ₹170 Cr ▼80.5% | ₹873 Cr ▲262.2% | ₹241 Cr ▲84.0% | ₹131 Cr | ₹0 Cr |
| Other Liabilities | ₹5.5K Cr ▲6.0% | ₹5.2K Cr ▲7.3% | ₹4.8K Cr ▲107.9% | ₹2.3K Cr ▲11.2% | ₹2.1K Cr ▲0.0% | ₹2.1K Cr ▲48.9% | ₹1.4K Cr ▼3.6% | ₹1.4K Cr ▲49.7% | ₹968 Cr |
| Total Liabilities | ₹28.1K Cr ▼2.5% | ₹28.8K Cr ▲4.2% | ₹27.7K Cr ▲132.7% | ₹11.9K Cr ▲22.7% | ₹9.7K Cr ▲6.3% | ₹9.1K Cr ▲43.2% | ₹6.4K Cr ▲25.6% | ₹5.1K Cr ▲67.6% | ₹3.0K Cr |
| Assets | |||||||||
| Fixed Assets | ₹19.1K Cr ▼0.9% | ₹19.3K Cr ▲1.4% | ₹19.0K Cr ▲318.2% | ₹4.5K Cr ▲6.9% | ₹4.3K Cr ▲18.5% | ₹3.6K Cr ▲115.6% | ₹1.7K Cr ▲4.0% | ₹1.6K Cr ▲406.3% | ₹316 Cr |
| CWIP | ₹655 Cr ▲66.2% | ₹394 Cr ▼52.3% | ₹826 Cr ▲192.9% | ₹282 Cr ▼48.7% | ₹550 Cr ▼21.5% | ₹701 Cr ▲88.4% | ₹372 Cr ▲17.4% | ₹317 Cr ▲574.5% | ₹47 Cr |
| Investments | ₹2.0K Cr ▼32.6% | ₹2.9K Cr ▲44.3% | ₹2.0K Cr ▼20.5% | ₹2.6K Cr ▲90.8% | ₹1.3K Cr ▲21.4% | ₹1.1K Cr ▼26.7% | ₹1.5K Cr ▲82.4% | ₹829 Cr ▼13.6% | ₹959 Cr |
| Other Assets | ₹6.3K Cr ▲2.2% | ₹6.2K Cr ▲7.4% | ₹5.8K Cr ▲28.8% | ₹4.5K Cr ▲26.9% | ₹3.5K Cr ▼4.6% | ₹3.7K Cr ▲31.9% | ₹2.8K Cr ▲21.2% | ₹2.3K Cr ▲36.4% | ₹1.7K Cr |
| Total Assets | ₹28.1K Cr ▼2.5% | ₹28.8K Cr ▲4.2% | ₹27.7K Cr ▲132.7% | ₹11.9K Cr ▲22.7% | ₹9.7K Cr ▲6.3% | ₹9.1K Cr ▲43.2% | ₹6.4K Cr ▲25.6% | ₹5.1K Cr ▲67.6% | ₹3.0K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹3.1K Cr ▲29.3% | ₹2.4K Cr ▲12.1% | ₹2.2K Cr ▲18.7% | ₹1.8K Cr ▲97.1% | ₹920 Cr ▼19.1% | ₹1.1K Cr ▲6.3% | ₹1.1K Cr | — |
| Investing CF | ₹-196 Cr ▲98.4% | ₹-12.6K Cr ▼506.6% | ₹-2.1K Cr ▼97.8% | ₹-1.1K Cr ▲23.2% | ₹-1.4K Cr ▼12.0% | ₹-1.2K Cr ▼180.3% | ₹-436 Cr | — |
| Financing CF | ₹-3.0K Cr ▼128.9% | ₹10.2K Cr ▲204560.0% | ₹5 Cr ▲100.7% | ₹-740 Cr ▼222.3% | ₹605 Cr ▲7662.5% | ₹-8 Cr ▲98.5% | ₹-531 Cr | — |
| Net Cash Flow | ₹-28 Cr ▼227.3% | ₹22 Cr ▼71.4% | ₹77 Cr ▲250.0% | ₹22 Cr ▼85.9% | ₹156 Cr ▲269.6% | ₹-92 Cr ▼189.3% | ₹103 Cr | — |
| Free Cash Flow | ₹2.4K Cr ▲26.0% | ₹1.9K Cr ▲7.0% | ₹1.8K Cr ▲79.4% | ₹987 Cr ▲169.4% | ₹-1.4K Cr ▼272.3% | ₹826 Cr ▼3.2% | ₹853 Cr | — |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 44d ▼4.3% | 46d ▲53.3% | 30d ▲25.0% | 24d ▲33.3% | 18d ▼5.3% | 19d ▼42.4% | 33d ▲50.0% | 22d |
| Inventory Days | 193d ▼11.9% | 219d ▲21.7% | 180d ▼4.3% | 188d ▼29.1% | 265d ▲9.1% | 243d ▲38.9% | 175d ▲5.4% | 166d |
| Days Payable | 121d ▲1.7% | 119d ▲32.2% | 90d ▼28.6% | 126d ▼22.2% | 162d ▲18.2% | 137d ▼5.5% | 145d ▲104.2% | 71d |
| Cash Conv. Cycle | 117d ▼19.9% | 146d ▲21.7% | 120d ▲39.5% | 86d ▼28.9% | 121d ▼3.2% | 125d ▲98.4% | 63d ▼46.2% | 117d |
| Working Capital Days | -1d ▲96.4% | -28d ▼152.8% | 53d ▲35.9% | 39d ▲62.5% | 24d ▼25.0% | 32d ▲6.7% | 30d ▼46.4% | 56d |
| ROCE | 14.0% ▼12.5% | 16.0% ▼38.5% | 26.0% ▲18.2% | 22.0% ▼31.3% | 32.0% ▼13.5% | 37.0% | — | — |
Source: Screener.in · Lower days = better efficiency
Deep Dive Analysis
About Mankind Pharma Limited
Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.[1]
Healthcare · Pharmaceuticals & Biotechnology
Related Analysis
Frequently Asked Questions
What is Mankind Pharma Limited share price today?▾
Mankind Pharma Limited (MANKIND) is currently trading at ₹2,332 on NSE, as of the last market session. Prices update daily after market close on MarketNetra.
Is Mankind Pharma Limited available in F&O (Futures & Options)?▾
Yes, Mankind Pharma Limited (MANKIND) is part of the NSE F&O segment with a lot size of 225 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Mankind Pharma Limited 52-week high and low?▾
Mankind Pharma Limited's 52-week high is ₹2,727 and the 52-week low is ₹1,910. The current price of ₹2,332 is 14.5% below the 52W high.
What is Mankind Pharma Limited P/E ratio?▾
Mankind Pharma Limited's current P/E ratio is 47.2. This indicates the market is paying ₹47.2 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Mankind Pharma Limited options?▾
Mankind Pharma Limited options are traded on NSE with monthly expiry contracts (lot size: 225 shares). To trade MANKIND options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.